These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12297363)

  • 1. In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials.
    Hilliard NJ; Johnson CN; Armstrong SH; Quarles S; Waites KB
    Int J Antimicrob Agents; 2002 Aug; 20(2):136-40. PubMed ID: 12297363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Activity of ertapenem and 19 other antimicrobial agents against beta-lactam-resistant Streptococcus pneumoniae and Haemophilus influenzae respiratory tract isolates].
    Gómez-Garcés JL; Alós JI; Alhambra A; Hernáiz C
    Enferm Infecc Microbiol Clin; 2005 Feb; 23(2):67-70. PubMed ID: 15743576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.
    Gosbell IB; Fernandes LA; Fernandes CJ
    Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.
    Pankuch GA; Davies TA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2002 Jan; 46(1):42-6. PubMed ID: 11751109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
    Stratton CW; Brown SD
    Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.
    Hovde LB; Rotschafer SE; Ibrahim KH; Gunderson B; Hermsen ED; Rotschafer JC
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):265-7. PubMed ID: 12729997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
    Zhanel GG; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of carbapenem antimicrobial agents against 264 penicillin-resistant Streptococcus pneumoniae isolates from Korea.
    Choi SH; Park SJ; Jun JB; Lee SR; Jeon MH; Kwon HH; Kim SC; Kim MN; Jeong JY; Woo JH; Kim YS
    Diagn Microbiol Infect Dis; 2007 May; 58(1):141-3. PubMed ID: 17368803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia.
    Livermore DM; Carter MW; Bagel S; Wiedemann B; Baquero F; Loza E; Endtz HP; van Den Braak N; Fernandes CJ; Fernandes L; Frimodt-Moller N; Rasmussen LS; Giamarellou H; Giamarellos-Bourboulis E; Jarlier V; Nguyen J; Nord CE; Struelens MJ; Nonhoff C; Turnidge J; Bell J; Zbinden R; Pfister S; Mixson L; Shungu DL
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1860-7. PubMed ID: 11353638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibilities of 176 clinical isolates of Streptococcus pneumoniae to 11 beta-lactams, erythromycin, and tetracycline.
    Vanhoof R; Carpentier M; Glupczynski Y; Gordts B; Magerman K; Nyssen HJ; Simon A; Surmont I; Van de Vyvere M; Van Landuyt H; Van Nimmen L; Van Noyen R
    Acta Clin Belg; 1996; 51(6):377-85. PubMed ID: 8997755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN; Sader HS; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and other respiratory pathogens from 12 Asian countries.
    Song JH; Ko KS; Lee MY; Park S; Baek JY; Lee JY; Heo ST; Kwon KT; Ryu SY; Oh WS; Peck KR; Lee NY
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):445-50. PubMed ID: 16949783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
    Kiremitci A; Dinleyici EC; Erben N; Durmaz G; Yargic ZA; Aybey AD; Usluer G
    Expert Opin Pharmacother; 2008 Jun; 9(9):1441-9. PubMed ID: 18518776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ertapenem: a new carbapenem.
    Odenholt I
    Expert Opin Investig Drugs; 2001 Jun; 10(6):1157-66. PubMed ID: 11772242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative in vitro activity of ertapenem against aerobic and anaerobic bacteria].
    Loza E; Morosini MI; Cantón R; Almaraz F; Reig M; Baquero F
    Rev Esp Quimioter; 2003 Jun; 16(2):209-15. PubMed ID: 12973459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
    Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.